TNFSF13 anticorps

N° du produit ABIN7566466

Cet anticorps Souris Monoclonal détecte spécifiquement TNFSF13 dans ELISA, IP et Func. Il présente une réactivité envers Humain.

Aperçu rapide pour TNFSF13 anticorps (ABIN7566466)

Antigène: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFSF13 est non-conjugé

Application: ELISA, Immunoprecipitation (IP), Functional Studies (Func)

Clone: Mahya-1

Détail du produit anti-TNFSF13 anticorps

Fonction: anti-APRIL (human), mAb (blocking) (Mahya-1) (preservative free)

Attributs du produit:

Monoclonal Antibody. Recognizes human APRIL. Does not recognize mouse APRIL or mouse and human BAFF. Applications: ELISA, FUNC (Blocking), IP. Isotype: Mouse IgG1 kappa. Clone: Mahya-1. Liquid. In PBS. The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are critical factors in the maintenance of the B cell pool and humoral immunity. APRIL binds to transmembrane activator and CAML interactor (TACI), B cell maturation antigen (BCMA), and heparan sulfate proteoglycans (HSPG) within the extracellular matrix or on the surface of cells such as plasma cells. APRIL maintains B cell homeostasis by acting at a later stage, modulating the function and survival of antigen-experienced B cells. APRIL (as well as BAFF) stimulates class-switch recombination (CSR), hence contributes to shaping humoral effector mechanisms. With regards to humoral memory, APRIL is involved in the establishment and survival of the long-lived plasma cell (LLPC) pool in the bone marrow (BM). APRIL is expressed by a number of myeloid-derived cell types including BM granulocytes, megakaryocytes, eosinophils and osteoclasts and by dendritic cells following exposure to IFNalpha, IFNgamma or CD40L. APRIL expression is induced during hematopoiesis in the bone marrow. APRIL expression is not limited to cells of myeloid origin, but can also be found in epithelial cells of the gut, tonsil, breast and skin. Finally, APRIL is expressed in tumor cell lines and human cancer cells of colon, thyroid and lymphoid origin. APRIL (a proliferation-inducing ligand) is implicated in several human autoimmune diseases with autoreactive B cell involvement, including systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), IgA nephropathy (IgAN) and rheumatoid arthritis (RA). APRIL might also function in enhancing proliferation of some tumor cells, especially B-cell malignancies.

The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are critical factors in the maintenance of the B cell pool and humoral immunity. APRIL binds to transmembrane activator and CAML interactor (TACI), B cell maturation antigen (BCMA), and heparan sulfate proteoglycans (HSPG) within the extracellular matrix or on the surface of cells such as plasma cells. APRIL maintains B cell homeostasis by acting at a later stage, modulating the function and survival of antigen-experienced B cells. APRIL (as well as BAFF) stimulates class-switch recombination (CSR), hence contributes to shaping humoral effector mechanisms. With regards to humoral memory, APRIL is involved in the establishment and survival of the long-lived plasma cell (LLPC) pool in the bone marrow (BM). APRIL is expressed by a number of myeloid-derived cell types including BM granulocytes, megakaryocytes, eosinophils and osteoclasts and by dendritic cells following exposure to IFN-alpha, IFN-gamma or CD40L. APRIL expression is induced during hematopoiesis in the bone marrow. APRIL expression is not limited to cells of myeloid origin, but can also be found in epithelial cells of the gut, tonsil, breast and skin. Finally, APRIL is expressed in tumor cell lines and human cancer cells of colon, thyroid and lymphoid origin. APRIL (a proliferation-inducing ligand) is implicated in several human autoimmune diseases with autoreactive B cell involvement, including systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), IgA nephropathy (IgAN) and rheumatoid arthritis (RA). APRIL might also function in enhancing proliferation of some tumor cells, especially B cell malignancies.

Purification: Puified

Pureté: >95 % (SDS-PAGE)

niveau d'endotoxine: <0.01EU/μg purified protein (LAL-test, Lonza)

Immunogène: Recombinant human APRIL (aa 98-233).

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: In PBS.

Agent conservateur: Without preservative

Conseil sur la manipulation: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.

Stock: 4 °C,-20 °C

Stockage commentaire:

Stable for at least 1 month after receipt when stored at +4°C.

Stable for at least 1 year after receipt when stored at -20°C.

Détails sur TNFSF13

Antigène: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Autre désignation: APRIL

UniProt: O75888

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response